文献速递前列腺癌

同步转移性激素敏感性前列腺癌患者接受雄激素剥夺治疗联合或不联合前列腺放疗的前列腺癌相关事件:HORRAD 试验数据

Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial.
PubMed 文献 · Eur Urol · 2024-09-20

HORRAD 试验第二次更新分析回顾性研究 328 例同步转移性激素敏感性前列腺癌患者,比较放疗组与非放疗组局部及非局部前列腺癌相关事件。放疗组局部事件 30 例 vs 非放疗组 50 例(p=0.04),局部干预发生时间显著延长(HR 0.61,95%CI 0.37-0.99,p=0.04)。作者结论:前列腺局部放疗显著延长局部无事件生存并减少局部前列腺癌相关干预。

要点

  • 放疗组局部事件 30 例 vs 非放疗组 50 例,差异有统计学意义(p=0.04)。
  • 局部干预发生时间放疗组显著长于非放疗组(HR 0.61,95%CI 0.37-0.99,p=0.04)。
  • 作者结论:局部放疗延长局部无事件生存并减少局部干预。

核心结论

  • 对同步转移性激素敏感性前列腺癌患者,前列腺局部放疗显著延长局部无事件生存并减少局部前列腺癌相关干预。

研究设计与样本

  • HORRAD 为多中心随机对照试验,最初纳入 2004 至 2014 年间诊断的 432 例同步转移性激素敏感性前列腺癌患者。
  • 第二次更新分析回顾性研究其中 328 例患者的局部和非局部前列腺癌相关事件及治疗。

主要发现

  • 局部事件发生率:放疗组 30 例事件 vs 非放疗组 50 例事件(p=0.04)。
  • 局部干预发生时间:放疗组较非放疗组显著延长(HR 0.61,95%CI 0.37-0.99,p=0.04)。
  • 结局指标包括局部事件(膀胱出口或输尿管梗阻、导尿、手术干预、输尿管支架和肾造瘘管)和非局部事件(输血、住院和疼痛性骨转移治疗)的发生率及治疗。
  • 组间差异采用粗 logistic 回归和校正 logistic 回归比较,局部事件发生时间采用 Kaplan-Meier 曲线和 Cox 回归分析评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究局限性包括其回顾性性质。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: A survival benefit was demonstrated for patients with low-volume synchronous metastatic hormone-sensitive prostate cancer (mHSPCa) when local radiotherapy to the prostate was added to androgen deprivation therapy. This study aims to determine the incidence of prostate cancer-related events and treatments in those who received and those who did not receive external beam radiotherapy for mHSPCa. METHODS: The HORRAD trial is a multicentre randomised controlled trial recruiting originally 432 patients with mHSPCa diagnosed between 2004 and 2014. In a second updated analysis, 328 patients were studied retrospectively for local and nonlocal prostate cancer-related events and treatments. Outcome measurements included the incidence and treatment of local (bladder outlet or ureter obstruction, catheterisation, surgical intervention, ureteric stents, and nephrostomy tubes) and nonlocal (blood transfusions, hospitalisations, and treatment for painful bone metastases) events. Differences between groups were compared using crude and adjusted logistic regression, while time to occurrence of local events was assessed with Kaplan-Meier curves and Cox regression analysis. KEY FINDINGS AND LIMITATIONS: A significant difference in the incidence of local events was observed: 30 events in the radiotherapy group versus 50 in the nonradiotherapy group (p = 0.04). Time to occurrence of local interventions was significantly longer in the radiotherapy group (hazard ratio 0.61, 95% confidence interval 0.37-0.99, p = 0.04). The study's limitations include its retrospective nature. CONCLUSIONS AND CLINICAL IMPLICATIONS: Local radiotherapy to the prostate prolongs local event-free survival significantly and reduces local prostate cancer-related interventions in patients with mHSPCa.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Boevé LMS, Hulshof MCCM, Verhagen PCMS, et al. Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial. Eur Urol. 2024. PMID: 39304427. doi:10.1016/j.eururo.2024.08.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。